E-4031 |
| Catalog No.GC13490 |
antiarrhythmic agent blocking the ATP-sensitive potassium channel
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 113558-89-7
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
IC50: 7.7 nM for hERG
E-4031 is an antiarrhythmic agent blocking the ATP-sensitive potassium channel.
ATP-sensitive potassium channels are distributed in tissues widely including muscle, pancreatic beta cells and brain. Their activity is regulated by adenine nucleotides, being activated by falling ATP and rising ADP levels. Thus, ATP-sensitive potassium channels link cellular metabolism with membrane excitability.
In vitro: It has been reported that E-4031 could induce EADs or TdP, and such induction correlated with a significant increase in variability of repolarization. In addition, E-4031 at 0.1 uM was able to significantly prolong cycle length, action potential duration, and depolarized maximum diastolic potential. E-4031could also reduce the upstroke velocity of the action potential as well as the diastolic depolarization rate [1].
In vivo: Animal study showed that E-4031 at 0.01 and 0.1 mg/kg could provide effective in-vitro plasma concentrations to significantly inhibit Ikr and thus delayed the repolarization beyond the initiation of diastole, leading to the inversion of electro-mechanical coupling, which provides an ideal proarrhythmic substrate [2]. Another sutdy found that E-4031 could prolong QT interval and ARI in all LV layers, though the magnitude of prolongation was greatest in Mid, particularly during bradycardia [3].
Clinical trial: Up to now, E-4031 is still in the preclinical development stage.
References:
[1]. Verheijck EE, et al. Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. Circ Res. 1995 Apr;76(4):607-15.
[2]. Izumi-Nakaseko H, et al. Effects of selective IKr channel blockade by E-4031 on ventricular electro-mechanical relationship in the halothane-anesthetized dogs. Eur J Pharmacol. 2014 Oct 5;740:263-70.
[3]. Izumi D, et al. Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog. Pacing Clin Electrophysiol. 2010 Aug;33(8):950-9.
| Cas No. | 113558-89-7 | SDF | |
| Chemical Name | N-(4-(1-(2-(6-methylpyridin-2-yl)ethyl)piperidine-4-carbonyl)phenyl)methanesulfonamide | ||
| Canonical SMILES | CC1=NC(CCN2CCC(C(C3=CC=C(NS(C)(=O)=O)C=C3)=O)CC2)=CC=C1 | ||
| Formula | C21H27N3O3S | M.Wt | 401.52 |
| Solubility | 25mg/mL in DMSO, 0.3mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4905 mL | 12.4527 mL | 24.9054 mL |
| 5 mM | 0.4981 mL | 2.4905 mL | 4.9811 mL |
| 10 mM | 0.2491 mL | 1.2453 mL | 2.4905 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *